| [1] |
NEWBURGER J W, TAKAHASHI M, GERBER M A, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association[J]. Circulation, 2004, 110(17): 2747-2771.
|
| [2] |
HARTOPO A B, SETIANTO B Y. Coronary artery sequel of Kawasaki disease in adulthood, a concern for internists and cardiologists[J]. Acta Med Indones, 2013, 45(1): 69-75.
|
| [3] |
RIFE E, GEDALIA A. Kawasaki disease: an update[J]. Curr Rheumatol Rep, 2020, 22(10): 75.
|
| [4] |
CAPITTINI C, EMMI G, MANNARINO S, et al. An immune-molecular hypothesis supporting infectious aetiopathogenesis of Kawasaki disease in children[J]. Eur J Immunol, 2018, 48(3): 543-545.
|
| [5] |
HARA T, NAKASHIMA Y, SAKAI Y, et al. Kawasaki disease: a matter of innate immunity[J]. Clin Exp Immunol, 2016, 186(2): 134-143.
|
| [6] |
HU P, JIANG G M, WU Y, et al. TNF-α is superior to conventional inflammatory mediators in forecasting IVIG nonresponse and coronary arteritis in Chinese children with Kawasaki disease[J]. Clin Chim Acta, 2017, 471: 76-80.
|
| [7] |
韦铭菲, 史俊展, 姚泽伟, 等. 川崎病性冠状动脉瘤破裂出血致急性心包压塞死亡一例[J]. 郑州大学学报(医学版), 2024, 59(1): 144-147.
|
| [8] |
ZHANG X F, XIN G D, SUN D J. Serum exosomal miR-328, miR-575, miR-134 and miR-671-5p as potential biomarkers for the diagnosis of Kawasaki disease and the prediction of therapeutic outcomes of intravenous immunoglobulin therapy[J]. Exp Ther Med, 2018, 16(3): 2420-2432.
|
| [9] |
SUN F Y, YUAN W F, WU H, et al. LncRNA KCNQ1OT1 attenuates sepsis-induced myocardial injury via regulating miR-192-5p/XIAP axis[J]. Exp Biol Med, 2020, 245(7): 620-630.
|
| [10] |
WANG Z S, ZHANG J Y, ZHANG S L, et al. miR-30e and miR-92a are related to atherosclerosis by targeting ABCA1[J]. Mol Med Rep, 2019, 19(4): 3298-3304.
|
| [11] |
LEHMAN T J, WALKER S M, MAHNOVSKI V, et al. Coronary arteritis in mice following the systemic injection of group B Lactobacillus casei cell walls in aqueous suspension[J]. Arthritis Rheum, 1985, 28(6): 652-659.
|
| [12] |
ABE M, RASTELLI D D, GOMEZ A C, et al. IL-1-dependent electrophysiological changes and cardiac neural remodeling in a mouse model of Kawasaki disease vasculitis[J]. Clin Exp Immunol, 2020, 199(3): 303-313.
|
| [13] |
CHENG Y R, QU X Y, DONG Z N, et al. Comparison of serum exosome isolation methods on co-precipitated free microRNAs[J]. Peer J, 2020, 8: e9434.
|
| [14] |
ZHANG Q, HUA W, WANG Y, et al. Clinical features of Kawasaki disease in children with an atypical age of onset [J]. Hong Kong J Paediatr, 2021, 26(4): 204-210.
|
| [15] |
FUKAZAWA R, KOBAYASHI T, MIKAMI M, et al. Nationwide survey of patients with giant coronary aneurysm secondary to Kawasaki disease 1999-2010 in Japan[J]. Circ J, 2017, 82(1): 239-246.
|
| [16] |
GORDON J B, DANIELS L B, KAHN A M, et al. The spectrum of cardiovascular lesions requiring intervention in adults after Kawasaki disease[J]. JACC Cardiovasc Interv, 2016, 9(7): 687-696.
|
| [17] |
NAKAMURA Y, ASO E, YASHIRO M, et al. Mortality among Japanese with a history of Kawasaki disease: results at the end of 2009[J]. J Epidemiol, 2013, 23(6): 429-434.
|
| [18] |
GORDON J B, KAHN A M, BURNS J C. When children with Kawasaki disease grow up: Myocardial and vascular complications in adulthood[J]. J Am Coll Cardiol, 2009, 54(21): 1911-1920.
|
| [19] |
STANGEL M, PUL R. Basic principles of intravenous immunoglobulin (IVIg) treatment[J]. J Neurol, 2006, 253(): V18-V24.
|
| [20] |
TAKAHASHI K, OHARASEKI T, YOKOUCHI Y. Pathogenesis of Kawasaki disease[J]. Clin Exp Immunol, 2011, 164(): 20-22.
|
| [21] |
KELLER S, SANDERSON M P, STOECK A, et al. Exosomes: from biogenesis and secretion to biological function[J]. Immunol Lett, 2006, 107(2): 102-108.
|
| [22] |
周孙欣, 霍 娜, 李红坤, 等. 人滑膜间充质干细胞外泌体中miR-429修复骨关节炎软骨损伤的作用初探[J]. 解放军医学杂志, 2025, 50(7): 882-889.
|
| [23] |
LU M M, YUAN S F, LI S C, et al. The exosome-derived biomarker in atherosclerosis and its clinical application[J]. J Cardiovasc Transl Res, 2019, 12(1): 68-74.
|
| [24] |
张向前, 韩 笑, 张 坤. 血清外泌体LncRNA GAS5在胃癌患者中的表达水平及其临床意义[J]. 临床检验杂志, 2025, 43(5): 336-340.
|
| [25] |
LI C, LI X L, GAO X, et al. microRNA-328 as a regulator of cardiac hypertrophy[J]. Int J Cardiol, 2014, 173(2): 268-276.
|
| [26] |
LU Y J, ZHANG Y, WANG N, et al. microRNA-328 contributes to adverse electrical remodeling in atrial fibrillation[J]. Circulation, 2010, 122(23): 2378-2387.
|
| [27] |
NTOUMOU E, TZETIS M, BRAOUDAKI M, et al. Serum microRNA array analysis identifies miR-140-3p, miR-33b-3p and miR-671-3p as potential osteoarthritis biomarkers involved in metabolic processes[J]. Clin Epigenetics, 2017, 9: 127.
|
| [28] |
ZHANG B X, SUN M Q, WANG J Z, et al. miR-671 ameliorates the progression of osteoarthritis in vitro and in vivo [J]. Pathol Res Pract, 2019, 215(7): 152423.
|
| [29] |
JIA H L, LIU C W, ZHANG L, et al. Sets of serum exosomal microRNAs as candidate diagnostic biomarkers for Kawasaki disease[J]. Sci Rep, 2017, 7: 44706.
|